The National Institute of Excellence in Health and Social Services (INESSS) in Quebec is asking health professionals, consumers and patients, and patient groups to submit their comments about Irinotecan Liposome (Onivyde®) for the treatment of metastatic pancreatic cancer. This medication is being evaluated to determine whether the government will provide access and reimbursement to patients.
Consumers or patient groups can submit comments on the potential effects of a drug product on the condition of patients or consumers. You can give input if you are a Quebec resident. You must provide input by 11:59pm Eastern Standard Time on October 10, 2017.
ONIVYDE: For the treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in adult patients who have been previously treated with gemcitabine-based therapy.ONIVYDE was evaluated in NAPOLI-1, the first global, phase III trial to demonstrate a positive outcome in patients with disease progression following gemcitabine-based therapy. Patients who received ONIVYDE in combination with 5-FU/LV saw significant improvements in median overall survival (45 per cent increase), progression-free survival (100 per cent increase) and objective response rate (16.2 per cent) relative to those who received 5-FU/LV alone (0.8 per cent).